http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2015200149-A1
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a2901e694724c2a759f619944cb7d2a4 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-164 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-56 |
filingDate | 2015-01-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ab245fe335e7899d9e26599e2701331b |
publicationDate | 2015-02-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | AU-2015200149-A1 |
titleOfInvention | Novel antitumoral use of cabazitaxel |
abstract | The invention relates to a cabazitaxel, which may be in base form or in the form of a hydrate or a solvate, in combination with prednisone or prednisolone, for its use as a medicament in the treatment of prostate cancer, particularly metastatic prostate cancer, especially for patients who are not catered for by a taxane-based treatment. |
priorityDate | 2009-10-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 89.